MedTrace Logo

Clinical Investigation of a Novel Spectacle Lens on Slowing Down Juvenile Myopia Progression

NCT06850168 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2025-08-07

No results posted yet for this study

Summary

The goal of this exploratory clinical trial is to evaluate the efficacy and safety of a test spectacle lens (standard single vision lens (SVL) during first year, and standard myopia control lens (MCL) in second year), designed with passive red-light emission, for the control of myopia progression in myopic children age 6 to 11 years old, both male and female, with no systemic or ocular anomalies. The main question it aims to answer is:

Does the test spectacle lens designed with passive red-light emission provide significant myopia control effect to children?

Researchers will compare the standard SVL designed with passive red-light emission to SVL (first year) and MCL designed with passive red-light emission to MCL (second year) to see if the test spectacle lens work to slow down myopia progression.

Participants will:

* Wear the study spectacles
* Visit Essilor R\&D Centre for follow-up sessions

Conditions

  • Myopia

Interventions

DEVICE

SVL

Dispensed to one eye in Year 1

DEVICE

SVL with passive red-light emission

Dispensed to the contralateral eye in Year 1.

DEVICE

MCL

Dispensed to one eye in Year 2 (if used SVL with passive red-light emission in Year 1).

DEVICE

MCL with passive red-light emission

Dispensed to the contralateral eye in Year 2 (if used SVL in Year 1).

Sponsors & Collaborators

  • Essilor International

    lead INDUSTRY

Principal Investigators

  • Andrew Tan · Essilor R&D Centre Singapore

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
6 Years
Max Age
11 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-26
Primary Completion
2027-10-31
Completion
2027-12-31

Countries

  • Singapore

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06850168 on ClinicalTrials.gov